Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...
AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...
A team of researchers has developed a new gene therapy for children with Dravet syndrome - a rare type of epilepsy in ...
A team of researchers has developed a new gene therapy for children with Dravet syndrome -- a rare type of epilepsy in children.
Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability, and even ...
Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...
Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children ...
In 2004, a research group at Peking University First Hospital discovered a mutation in the gene coding for a sodium-channel subunit in individuals with a rare and serious disorder called inherited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback